US · Healthcare · Biotechnology
EPS came in at -0.36 against a street estimate of -0.36 — a beat of 0.0%.
Analysts rate Phio Pharmaceuticals Corp a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $14.00.
| Fund | Stake |
|---|---|
| Jane Street Group LLC | 1.01% |
| Geode Capital Management, LLC | 0.99% |
| Vanguard Capital Management, LLC | 0.81% |
| Delaware Management Holdings Inc | 0.43% |
| Cetera Investment Advisers | 0.41% |
| Citadel Advisors Llc | 0.41% |
| Vanguard Fiduciary Trust Co | 0.33% |
| Northern Trust Corp | 0.24% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Phio Pharmaceuticals Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.